WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid Leukemia

Published:2020-12 Issue:12 Volume:20 Page:e998-e1009
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Šálek Cyril,Vydra Jan,Cerovská Ela,Šestáková Šárka,Ransdorfová Šárka,Válková Veronika,Cetkovský Petr,Remešová Hana

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference37 articles.

1. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study;Bruggemann;Leukemia,2019

2. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies;van Dongen;Blood,2015

3. Genomic classification and prognosis in acute myeloid leukemia;Papaemmanuil;N Engl J Med,2016

4. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party;Schuurhuis;Blood,2018

5. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel;Dohner;Blood,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. WT1 Expression Is Associated with Poor Overall Survival after Azacytidine and DLI in a Cohort of Adult AML and MDS Patients;Cancers;2024-09-04

2. Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy;International Journal of Clinical Oncology;2024-02-09

3. Wilms’ tumor gene 1 in hematological malignancies: friend or foe?;Hematology;2023-09-05

4. Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia;Hematology;2022-09-06

5. Measurable Residual Disease in High-Risk Acute Myeloid Leukemia;Cancers;2022-03-01